share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  06/14 16:21
Moomoo AI 已提取核心訊息
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
2024年6月10日，專注於治療睡眠相關呼吸障礙的醫療科技公司Vivos Therapeutics，Inc.與New Seneca Partners Inc.附屬公司V-CO Investors LLC簽署了一份證券購買協議。協議涉及定向增發的私募股權和認股權憑證交易，Vivos向V-CO出售股票和認股權憑證，從而使Vivos的營業收入達到了750萬美元。這些資金將用於公司的一般性經營用途和運營資金。同時，Vivos子公司VSI Providers，PLLC和Rebis Health Holdings，LLC簽署了一份戰略聯盟協議，共同推銷和分銷針對睡眠呼吸障礙治療方案的解決方案。此外，Viv...展開全部
2024年6月10日，專注於治療睡眠相關呼吸障礙的醫療科技公司Vivos Therapeutics，Inc.與New Seneca Partners Inc.附屬公司V-CO Investors LLC簽署了一份證券購買協議。協議涉及定向增發的私募股權和認股權憑證交易，Vivos向V-CO出售股票和認股權憑證，從而使Vivos的營業收入達到了750萬美元。這些資金將用於公司的一般性經營用途和運營資金。同時，Vivos子公司VSI Providers，PLLC和Rebis Health Holdings，LLC簽署了一份戰略聯盟協議，共同推銷和分銷針對睡眠呼吸障礙治療方案的解決方案。此外，Vivos、Airway Integrated Management Company，LLC和V-CO之間簽訂了一份管理服務協議，在戰略聯盟方面，V-CO將提供相關管理和諮詢服務。私募股權和戰略協議於2024年6月12日在新聞發佈會上宣佈，旨在通過合作增強Vivos的營業收入及潛在利潤。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息